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Abstract 
Background: Transplantation of islets of Langerhans (islets) is a promising technique 
for treating insulin-dependent diabetes mellitus (type I). One unsolved issue is the early 
graft loss due to inflammatory reactions triggered by blood coagulation and complement 
activation that occurs immediately after transplantation into the liver through the portal 
vein. Several proposed approaches for improvement of the graft survival include 
heparin coating and covalent poly(ethylene glycol) (PEG) conjugation. We previously 
have studied the improvement of graft survival by modification of islet surfaces using 
amphiphilic PEG-conjugated phospholipid and bioactive molecules. Here we analyzed 
the effect of PEG-modification on the improvement of graft survival immediately after 
intraportal transplantation into streptozotocin-induced diabetic mice.  
Methods: The surface of hamster islets was modified with PEG-lipid. PEG-lipid 
modified islets (PEG-islets) were transplanted into the liver through the portal vein of 
streptozotocin-induced diabetic mice. We measured the graft survival periods and blood 
insulin levels immediately after intraportal transplantation to determine the cell damage 
to islets. Histocytochemical analyses of liver were also performed post intraportal 
transplantation. 
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Results: The graft survival of PEG-islets was significantly prolonged compared with 
bare islets in livers of diabetic mice. Reduction of blood insulin level within 60 min 
after transplantation of PEG-islets suggests that the cell damage observed immediately 
after transplantation could be suppressed by surface modification with PEG in 
comparison with bare islets. 
Conclusion: Our approach for the improvement of graft survival will be useful in the 
clinical setting. 
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Introduction 
Although transplantation of islets of Langerhans (islets) is still an experimental 
procedure, this approach has been proven to be a safe and effective method for treating 
patients with insulin-dependent diabetes mellitus (type I). Notably, the success achieved 
with the Edmonton protocol has established clinical islet transplantation as an 
alternative to pancreas transplantation [1, 2]. However, some aspects of islet 
transplantation remain to be improved, including increase of islet isolation efficiency, 
improvement in islet preservation, increase in the efficacy of immunosuppressive drug 
dosage protocols, and reduction of islet loss in the early phase following transplantation. 
Among these issues, graft loss poses the most serious limitations for current islet 
transplantation protocols. Transplantation of islets from a single donor pancreas is not 
sufficient to achieve normoglycemia in a patient [2], suggesting that many islets are lost 
soon after intraportal transplantation. 
Innate immune reactions are involved in the destruction of islets exposed to fresh blood 
in the portal vein [3-7]. Blood coagulation and complement systems are activated upon 
exposure of islets to fresh blood components; chemotactic factors, tissue factor, 
chemokines, and other inflammatory mediators are released during this early phase, 
which induce instant blood-mediated inflammatory reactions resulting in graft loss [5]. 
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Some approaches to regulate early coagulation and blood-mediated inflammatory 
reactions, such as administration of Melagatran [6] and dextran sulfate [7], have been 
studied, and suppression of these reactions has improved transplantation success by 
reducing islet loss in animal models. However, it is difficult to apply these methods to 
the clinical situation because systemic administration is associated with a risk of 
bleeding. Several methods have been reported for improvement of graft survival in the 
liver, such as coating of islet surface with polymers and bioactive molecules [8,9]. 
Contreras et al. reported the improvement of graft survival in the liver by covalent 
conjugation of poly(ethylene glycol) to the islet surface and transfection of an apoptosis 
suppressing gene [8]. Recently, Nilsson et al. proposed a new method for preventing 
instant blood-mediated inflammatory reactions by coating islets with heparin to inhibit 
surface thrombosis formation following transplantation [9].  
We previously studied the effect of surface modification of living cells and islets using 
amphiphilic polymers such as PEG-conjugated phospholipid and poly(vinyl alcohol) 
with alkyl side chains on the improvement of graft survival during cell transplantation 
[10-14]. The results from our methods are promising, as PEG-lipid derivatives can be 
immobilized to the cell surface via hydrophobic interactions between the lipid bilayer 
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membrane. Furthermore, a thin PEG layer can form on the islet surface without 
cytotoxicity and volume increase. 
In this paper, we evaluated the efficacy of PEG-modification on the improvement of 
graft survival immediately after transplantation in the liver through the portal vein of 
streptozotocin-induced diabetic mice. We predicted that surface modification with PEG 
could suppress the coagulation reactions and inflammatory reactions that mediate islet 
loss during the early phase of intraportal transplantation. We studied the graft survival 
periods, performed histochemical analysis and measured blood insulin levels 
immediately after intraportal transplantation to determine the cell damage to islets. 
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Materials and methods 
Materials 
α-N-Hydroxysuccinimidyl-ω-maleimidyl poly(ethylene glycol) (NHS-PEG-Mal, Mw: 
5000) was purchased from Nektar Therapeutics (San Carlos, USA). We purchased 1, 2-
Dipalmitoyl-sn-glycerol-3-phosphatidylethanolamine (DPPE) from NOF Corporation 
(Tokyo, Japan). Dichloromethane, chloroform, N, N’-dimethylformamide (DMF), 
diethyl ether, streptozotocin (STZ) and tri-sodium citrate dehydrate were obtained from 
Nacalai Tesuque (Kyoto, Japan). ICN Biomedicals Inc (Aurora, OH) supplied cystein. 
Fluorescein isothiocyanate (FITC) and Hoechst 33342 were purchased from Dojindo 
Laboratories (Kumamoto, Japan). Alexa 488-labeled goat anti-guinea pig IgG, 
minimum essential medium (MEM), HEPES buffer solution and Medium 199 were 
purchased from Invitrogen Co. (Carlsbad, USA). Fetal bovine serum (FBS) was 
obtained from BioWest (Miami, USA), and phosphate-buffered saline (PBS) from 
Nissui Pharmaceutical Co. Ltd. (Tokyo, Japan). Enzyme-linked immunosorbent assay 
(ELISA) kits for the insulin assay were from Shibayagi Co., Ltd. (Gunma, Japan). 
Tissue-Tek was purchased from Sakura Finetechnical Co. Ltd. (Tokyo, Japan). Goat 
normal serum and polyclonal guinea pig anti-insulin were obtained from Dako 
(Glostrup, Denmark). We purchased 10% Formalin solution and Triton X-100 from 
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Wako Pure Chemical (Osaka, Japan). Isoflurene was purchased from Abbott Japan Co., 
Ltd. (Japan).  
 
Synthesis of PEG-conjugated phospholipid (PEG-lipid) 
Mal-PEG-lipid was synthesized by first dissolving NHS-PEG-Mal NHS-PEG-Mal (180 
mg) and DPPE (20 mg) in chloroform and stirring for 24 h at RT. After precipitation 
with diethyl ether, Mal-PEG-lipid was obtained as a white powder (190 mg, yield 80%).  
1H-NMR (CDCl3, 400 MHz, δ ppm): 0.88 (t, 6H, -CH3), 1.25 (br, 56H, -CH2-) 3.64 (br, 
480H, PEG), 6.71 (s, 2H, -HC=CH-, maleimide). 
In this experiment, the maleimide group was previously deactivated by the addition of 
cystein. FITC-labeled PEG-lipid [12], which has a similar structure and activity as 
PEG-lipid, was visualized in islets by confocal laser scanning microscopy (FLUOVIEW 
FV500, Olympus, Tokyo, Japan).  
 
Preparation of PEG-lipid-modified islets 
Islets were isolated from pancreases of Syrian hamsters (7-8 weeks, females, Japan SLC, 
Inc., Shizuoka, Japan) by collagenase digestion [15]. The islets were cultured for 4 days 
after isolation to remove or sediment cells that were damaged during the isolation 
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procedure; cells were cultured in Medium 199 with 10% FBS, 8.8 mM HEPES buffer, 
100 units/mL penicillin, 100 µg/mL streptomycin, and 8.8 U/mL heparin. A PEG-lipid 
solution (500 µg/mL in 100 µL of MEM) was added to islets suspended in serum-free 
MEM, and the mixture was incubated for 1 h at RT. After washing with serum-free 
MEM, PEG-lipid-modified islets were transplanted into the livers of diabetic mice.  
 
Static insulin secretion test by glucose stimulation 
Static insulin secretion tests were performed using 100 PEG-islets to evaluate their 
ability to secrete insulin in response to changes in glucose concentration. Bare islets 
were used as a control. Islets were exposed to 0.1 g/dl, then 0.3 g/dl, and finally 0.1 g/dl 
of glucose in Krebs-Ringer solution for 1 hour each at 37°C. The solutions were 
collected after the one-hour incubation in each glucose concentration, and insulin 
concentrations were determined in each solution by ELISA. 
 
Transplantation of PEG-islets into livers of STZ-induced diabetic mice 
Balb/c mice were used as recipients of islets and PEG-islets. Diabetes was induced in 
Balb/c mice (6 weeks, males, Japan SLC, Inc.) by intraperitoneal injection of STZ (230 
mg/kg body weight in citrate buffer, pH 4.5) ten days prior to transplantation. An 
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animal was considered diabetic when its plasma glucose level exceeded 400 mg/dl in 
two consecutive measurements. 
PEG-islets or control islets (500 or 1000 islets) were transplanted into the liver through 
the portal vein of STZ-induced diabetic mice, which were anesthetized during surgery 
by mask inhalation of Isoflurane using a specialized instrument (400 Anesthesia Unit; 
Univentor, Malta); the Isoflurane concentration was 4.5–5.0 % induction and 2.0 for 
maintenance with airflow rate of 200 ml/min. Diabetic mice were treated with either 
500 or 1000 control islets or PEG-islets. Mice were housed in cages with free access to 
food and water. Non-fasting plasma glucose levels were measured using a glucose 
sensor (DIAmeter-α glucocard; Arkray, Kyoto, Japan) between 11 a.m. and 1 p.m. 
before and after transplantation. Blood samples were taken from the subclavian vein. 
Graft failure was defined as two consecutive plasma glucose level determinations ≥200 




Mice were sacrificed after transplantation of islets or PEG-islets into the liver through 
portal vein of diabetic mice for 1 hr or 1 day. Livers were removed, washed with saline, 
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immersed in 10% formalin solution, and incubated for 2 days at RT. The formalin 
solution was removed and the livers were sequentially maintained in 3% and 10% 
sucrose in PBS for 2 days, followed by incubation in 20% sucrose in PBS for 2 days at 
RT. Livers were then embedded in Tissue-Tek for freezing. The frozen specimens were 
sliced (6-μm thick) by a cryostat (CM 3050S IV, Leica, Solms, Germany) and sections 
were permeabilized with 0.2% Triton X-100 in PBS at RT for 15 min. The samples 
were then treated with 10% normal goat serum in PBS for 1 h to block non-specific 
binding of antibodies. Sections were treated with 1% polyclonal guinea pig anti-insulin 
in PBS containing 3% goat normal serum for 3.5 hr at RT, followed by washing with 
PBS. The samples were then incubated with fluorescent labeled secondary antibody, 
0.2% Alexa 488 Goat anti-guinea pig IgG in PBS containing 3% goat normal serum at 
RT for 1.5 h. Cell nuclei were counterstained with Hoechst 33342. The stained sections 
were analyzed using fluorescence microscopy (BX51, Olympus Optical Co. Ltd., Tokyo, 
Japan). The sliced sections were also stained with hematoxylin-eosin (HE) using a 
conventional staining method. 
  
Determination of insulin levels in blood after intraportal transplantation of PEG-
islets 
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After transplantation of control or PEG-islets (1000 islets) into the liver of diabetic mice 
through the portal vein, blood was taken from the subclavian vein at 15, 30, 60 min and 
centrifuged to obtain plasma. Hamster insulin in the plasma of mice was determined by 
ELISA. 
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Results 
Surface modification of islets with PEG-lipid 
We previously studied the modification of islet surfaces with amphiphilic polymers 
such as PEG-conjugated phospholipid and poly(vinyl alcohol) with alkyl side chains for 
the improvement of graft survival [10-14]. Our method is promising for intraportal 
transplantation of islet as no damage to cell function was observed and no volume 
increase of islets was detected after modification of islet surface. 
In this study, we used amphiphilic PEG-lipid (shown in Fig. 1a) for modification of islet 
surfaces and predicted that the surface modification with PEG could suppress the 
inflammatory and coagulation reactions that mediate islet loss immediately after 
intraportal transplantation. The maleimide group at the end of the PEG chain can be 
used to immobilize bioactive molecules to the islet surface. Our aim was to evaluate the 
efficacy of PEG on islet surfaces to improve graft survival, therefore the maleimide 
group was deactivated by cystein prior to surface modification of islets. Islets were 
treated with a mixture of FITC-labeled PEG-lipid and PEG-lipid, and clearly detectable 
fluorescence was observed at the periphery of islets, indicating that the PEG chain was 
incorporated on the surface of islets (Fig. 1b). Furthermore, the hydrophobic lipid 
portion of PEG-lipid was observed to be spontaneously incorporated into the lipid 
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bilayer membrane of islets. These results indicate that PEG-lipid can form a layer on the 
islet surface without apparent damage to islet morphology. 
 
Insulin secretion by glucose stimulation 
Next we examined the ability of PEG-islets to control insulin release in response to 
glucose level changes using a glucose stimulation test; the results are summarized in Fig. 
2. No significant difference in insulin release was observed between control islets and 
PEG-islets. When the glucose concentration was increased from 0.1 g/dL to 0.3 g/dL, 
both control and PEG-islets increased insulin release compared to basal levels. When 
islets were re-exposed to 0.1 g/dL, insulin release returned to basal levels. These results 
indicate that the PEG-lipid surface modification did not affect the ability of islets to 
regulate and release insulin. 
 
Intraportal transplantation into liver of STZ-induced diabetic mice 
We next evaluated the efficacy of PEG-modification on the improvement of graft 
survival immediately after intraportal transplantation. Hamster islets were transplanted 
into the livers of STZ-induced diabetic mice through the portal vein. This 
transplantation is a concordant xenotransplantation model. Recipient mice were not 
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treated with immuno-suppressive therapy. Figure 3 shows changes in non-fasting blood 
glucose levels of recipient mice after intraportal transplantation of either 500 or 1000 
bare islets or PEG-islets. In this xenotransplantation model, the blood glucose level 
normalized after transplantation of islets; however, levels returned to hyperglycemic 
levels around 7 days because the grafts were lost by immune rejection in recipient mice. 
In the mice transplanted with 500 islets (Fig. 3a), the blood glucose levels in all mice 
except one were not normalized 1 day after transplantation. Normoglycemia was 
achieved in 4 of 9 mice at 3 days and blood glucose levels were maintained for several 
days. At 7 days post-transplantation, most mice returned to hyperglycemic states. These 
results indicated that induction of islet cell damage occurred immediately after 
transplantation into the liver, and some of islets were destroyed, resulting in loss of 
function. The blood glucose level could not be properly regulated by the remaining 
islets during the early phase following post transplantation. Upon transplantation of 
1000 islets (Fig. 3b), normoglycemia was achieved in all mice at 2 days and continued 
until grafts were rejected (around 7 days). In contrast, when 500 PEG-islets were 
transplanted, 5 of 6 mice were normoglycemic at 2 days and this was maintained until 
the graft was rejected (around 7 days). On transplantation of 1000 PEG-islets, all mice 
were normoglycemic at 2 days, and this was also maintained until the graft was rejected 
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(around 7 days). The period of graft survival in recipients of control and PEG-islets 
transplantation are summarized in Table 1. We found a significant difference between 
the period of graft survival upon transplantation of 500 control and PEG-islets. These 
results indicate that the islet damage that occurs immediately after transplantation into 
the liver could be suppressed by surface modification of islets with PEG-lipids. The 
period of graft survival was prolonged, although the immune rejection reaction could 
not be suppressed. On the other hand, we did not observe any significant difference in 
graft survival between recipients of 1000 control and PEG-islets. We speculate that 
mice transplanted with 500 control islets did not receive sufficient islets, as most were 
destroyed after transplantation and blood glucose levels could not be controlled. On the 
other hand, in mice transplanted with 500 PEG-islets, there were sufficient islets 
remaining, as cell damage to islets could be suppressed by surface modification with 
PEG-lipid; furthermore, blood glucose levels could be normalized, indicating the 
improvement of graft survival. For mice transplanted with 1000 control islets, there 
were sufficient islets remaining to control blood glucose levels, despite the loss of some 
islets. These results suggested that it is possible to suppress complement activation and 
blood coagulation-mediated inflammatory reactions that induce cell damage to islets 
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immediately after transplantation by modification of islet surfaces with PEG-lipids; this 
approach, however, does not suppress immune rejection reactions.  
Livers were retrieved from recipient mice after transplantation of control or PEG-islets 
through the portal vein at 1 hr and 1 day and subjected to histochemical analyses. After 
control islet transplantation at 1 hr (Fig. 4a), islets were damaged and destroyed in the 
blood vessel of the liver. Aggregation of red blood cells was observed around destroyed 
islets, indicating platelet aggregation and blood coagulation on the surface of islets. Cell 
damage to some islets was also observed after transplantation for 1 day (Fig. 4a). 
However, in livers of mice transplanted with PEG-islets, most islets were not damaged 
and remained intact in blood vessels of liver after transplantation for 1 hr (Fig. 4b and c). 
The same results were observed 1 day after transplantation. These histochemical 
analyses support the finding that the period of graft survival is prolonged after 
transplantation of PEG-islets. 
 
Determination of insulin levels in blood after intraportal transplantation of PEG-
islets 
To determine plasma insulin levels, blood was taken from the subclavian vein 15, 30 
and 60 min after intraportal transplantation of control and PEG-islets. When islets 
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undergo cell damage, large amounts of insulin from the islets are released into the blood 
and the blood insulin levels transiently increase [9]. Therefore, the degree of cell 
damage to islets can be linked to the blood insulin level. In mice transplanted with 
control islets, high levels of insulin (~27 ng/mL) were detected 15 min after 
transplantation (Fig. 5). The insulin was still observed at 30 and 60 min, although the 
amount of released insulin gradually reduced. These results indicated that islets were 
damaged, resulting in the release of large amounts insulin into the blood immediately 
after transplantation. On the other hand, in mice transplanted with PEG-islets, the 
release of insulin was considerably suppressed immediately after transplantation (~7 
ng/mL), indicating that islet cell damage was suppressed by PEG-lipid modification. 
Thus, this indicates the possibility to improve the biocompatibility of islets by surface 
modification with PEG-lipids. 
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Discussion 
Several groups have attempted to improve graft survival of islets by modification of 
islet surfaces [8,9,16,17]. Byon et al. reported improved graft survival of islets upon 
covalent bonding of PEG to cell membrane proteins and low dose of immuno-
suppressive therapy by transplantation under the kidney capsule. However, it is difficult 
to expect in the current clinical setting that surface modification of islets by PEG would 
improve transplantation under kidney capsules [18], as clinical islet transplantation to 
the liver is performed through the portal vein, and islets are exposed to blood 
components. On the other hand, when islets were transplanted under kidney capsules, 
cells are not exposed to blood components. The periods of graft survival are quite 
different in transplantation between these sites [18]. When islets are exposed to fresh 
blood in the portal vein, the blood coagulation and complement systems are activated, 
and chemotactic factors, tissue factor, chemokines, and other inflammatory mediators 
are released during the early phase of transplantation. These factors are induced by 
instant blood-mediated inflammatory reactions, resulting in graft loss and reduction of 
graft survival in the liver. Therefore, for future clinical islet transplantation, it is 
necessary to examine the efficacy of surface modification of islets by transplantation 
into liver. Several reports have examined the effect on transplantation success when 
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transplanting surface modified islets into livers of diabetic animals [8,9]. Contreras et al. 
reported that the graft survival of porcine islets in livers of NOD-SCID mice was 
improved by the transfection of an apoptosis suppressing gene and covalent PEG-
surface modification [8]. Nilsson et al. reported that the graft survival of porcine islets 
could be improved by modifying the surface of islets with heparin [9], and found that 
the heparin coating suppressed blood coagulation and activation of complement systems. 
In this study, we modified the surface of islets with amphiphilic PEG-lipid and 
examined the ability of the surface modification to improve graft survival in the liver. 
Recently we also immobilized bioactive molecules such as fibrinolytic urokinase using 
amphiphilic polymers to improve graft survival of islets in the liver. We have predicted 
that the surface modification with PEG and urokinase could suppress the inflammatory 
and coagulation reactions that mediate islet loss immediately after intraportal 
transplantation. PEG-lipid was spontaneously anchored to the lipid bilayer of cell 
membrane through hydrophobic interactions without cytotoxicity. Therefore, it is 
possible for a thin PEG layer to form on the islet surface without volume increase. PEG-
lipid has been widely used for the surface modification of liposomes to improve 
biocompatibility and prolong the circulation time in vivo in drug delivery systems 
[19,20]. Complement activation and platelet aggregation are suppressed by the surface 
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modification of liposome with PEG-lipid [21,22]. Our group studied the interaction 
between serum components and PEG-immobilized substrate by surface plasmon 
resonance and did not find activation of complement on the PEG-immobilized substrate 
[23]. In this study, PEG-lipid modified hamster islets were transplanted into livers of 
STZ-induced diabetic mice through the portal vein. We predicted that complement 
activation and platelet aggregation could be suppressed in the early phase using the 
PEG-lipid modified surface, as seen for PEG-liposomes and PEG-immobilized substrate. 
The graft survival of PEG-islets was significantly prolonged compared with bare islets 
in livers of diabetic mice (Fig. 3). Reduction of blood insulin level within 60 min after 
transplantation suggests that the cell damage observed immediately after transplantation 
could be suppressed by surface modification with PEG (Fig. 5). Platelet activation and 
complement system activation is thought to be suppressed using islets modified with 
PEG-lipids, as seen with PEG-liposomes and PEG-immobilized substrate. However, it 
was not possible to suppress immune-rejection reactions in recipient mice during later 
phases. Future studies should seek to improve stable and thick polymer layers on the 
islet surface and reveal the mechanism for prevention of graft loss with PEG 
modification in vivo and in vitro. 
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Conclusions 
A thin PEG layer could form on the surface of islets using PEG-lipids without volume 
increase and cytotoxicity. Blood coagulation and activation of complement systems, 
which was induced immediately after intraportal transplantation, could be suppressed 
using the PEG-lipid modified islets in transplantation, and usually observed islet 
damage during transplantation was suppressed. Furthermore, the period of graft survival 
was significantly improved. Together these findings suggest that our approach described 




This study was supported in part by CREST and JST, and by a Grant-in-Aid for 
Scientific Research (A) (No. 18200034) from the Ministry of Education, Culture, Sports, 
Science and Technology (MEXT) of Japan and the Ministry of Health, Labor and 
Welfare of Japan (H20-007). 
 - 25 - 
References 
(1) Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with 
type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. 
N. Engl. J. Med. 2000; 343: 230-238. 
(2) Ryan EA, Lakey JR, Rajotte RV, et al. Clinical outcomes and insulin secretion 
after islet transplantation with the Edmonton protocol. Diabetes 2001; 50: 710-
719. 
(3) Moberg L, Johansson H, Lukinius A, et al. Production of tissue factor by 
pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical 
islet transplantation. Lancet 2002; 360: 2039–2045. 
(4) Johansson H, Lukinius A, Moberg L, et al. Tissue factor produced by the 
endocrine cells of the islets of Langerhans is associated with a negative outcome 
of clinical islet transplantation. Diabetes 2005; 54: 1755–1762. 
(5) van der Windt DJ, Bottino R, Casu A, Campanile N, Cooper DK. Rapid loss of 
intraportally transplanted islets: an overview of pathophysiology and preventive 
strategies. Xenotransplantation 2007; 14: 288-297. 
(6) Ozmen L, Ekdahl KN, Elgue G, Larsson R, Korsgren O, Nilsson B. Inhibition of 
thrombin abrogates the instant blood-mediated inflammatory reaction triggered by 
 - 26 - 
isolated human islets: possible application of the thrombin inhibitor melagatran in 
clinical islet transplantation. Diabetes 2002; 51: 1779–1784. 
(7) Johansson H, Goto M, Dufrane D, et al. Low molecular weight dextran sulfate: a 
strong candidate drug to block IBMIR in clinical islet transplantation. Am. J. 
Transplant. 2006; 6: 305–312. 
(8) Contreras JL, Xie D, Mays J, et al. A novel approach to xenotransplantation 
combining surface engineering and genetic modification of isolated adult porcine 
islets. Surgery 2004; 136, 537-547. 
(9) Cabric S, Sanchez J, Lundgren T, et al. Islet surface heparinization prevents the 
instant blood-mediated inflammatory reaction in islet transplantation. Diabetes 
2007; 56: 2008-2015. 
(10) Teramura Y, Iwata H. Islets surface modification prevents blood-mediated 
inflammatory responses. Bioconjugate Chem. 2008; 19: 1389-1395. 
(11) Totani T, Teramura Y, Iwata H. Immobilization of urokinase to islet surface by 
amphiphilic poly (vinyl alcohol) carrying alkyl side chains. Biomaterials 2008; 
29: 2878-2883. 
 - 27 - 
(12) Miura S, Teramura Y, Iwata H. Encapsulation of islets with ultra-thin polyion 
complex membrane through poly(ethylene glycol)-phospholipids anchored to cell 
membrane. Biomaterials 2006; 27: 5828-5835. 
(13) Teramura Y, Kaneda Y, Iwata H. Islet-encapsulation in ultra-thin layer-by-layer 
membranes of poly(vinyl alcohol) anchored to poly(ethylene glycol)-lipids in the 
cell membrane. Biomaterials 2007; 28: 4818-4825. 
(14) Teramura Y, Kaneda Y, Totani T, Iwata H. Behavior of synthetic polymers 
immobilized on cell membrane. Biomaterials 2008; 29: 1345-1355. 
(15) Iwata H, Takagi T, Shimizu H, Yamashita K, Kobayashi K, Akutsu T. Agarose 
for bioartificial pancreas. J. Biomed. Mater. Res. 1992; 26: 967-977. 
(16) Lee DY, Park SJ, Nam JH, Byun Y. A new strategy toward improving 
immunoprotection in cell therapy for diabetes mellitus: long-functioning 
PEGylated islets in vivo. Tissue Eng. 2006; 12: 615-623. 
(17) Yun Lee D, Hee Nam J, Byun Y. Functional and histological evaluation of 
transplanted pancreatic islets immunoprotected by PEGylation and cyclosporine 
for 1 year. Biomaterials. 2007; 28: 1957-1966. 
 - 28 - 
(18) Goto M, Johansson H, Maeda A, Elgue G, Korsgren O, Nilsson B. Low molecular 
weight dextran sulfate prevents the instant blood-mediated inflammatory reaction 
induced by adult porcine islets. Transplantation 2004; 77: 741-747. 
(19) Zalipsky S. Functionalized Poly(ethylene glycol) for preparation of biologically 
relevant conjugates. Bioconjugate Chem 1995; 6: 150-165. 
(20) Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipatic poly(ethylene 
glycol)s effectively prolong the circulation time of liposome. FEBS Lett 1990; 
268: 235-237. 
(21) Bradley AJ, Devine DV, Ansell SM, Janzen J, Brooks DE. Inhibition of liposome-
induced complement activation by incorporated poly(ethylene glycol)-lipids. Arch. 
Biochem. Biophys. 1998; 357: 185-194. 
(22) Chiu GN, Bally MB, Mayer LD. Effects of phosphatidylserine on membrane 
incorporation and surface protection properties of exchangeable poly(ethylene 
glycol)-conjugated lipids. Biochim Biophys Acta. 2002; 18: 37-50. 
(23) Arima Y, Toda M, Iwata H. Complement activation on surfaces modified with 
ethylene glycol units. Biomaterials. 2008; 29: 551-560.  
 - 29 - 
Figure Captions 
Figure 1. (a) Chemical structure of PEG-conjugated DPPE (PEG-lipid). (b) Confocal 
laser scanning images of FITC-PEG-lipid-modified islets from hamsters. PEG-lipid can 
be introduced on the surface of islets by hydrophobic interaction. The hydrophobic lipid 
portion of PEG-lipid was spontaneously incorporated into the lipid bilayer membrane of 
islets. 
 
Figure 2. Assessment of insulin release in glucose stimulated islets. The amounts of 
insulin secreted from PEG-islets (black bars) and control bare islets (white bars) in 
response to glucose concentration changes (0.1, 0.3, 0.1 g/dL) were determined by 
ELISA. Results are expressed as mean + SD; n = 3. 
 
Figure 3. Changes in non-fasting blood glucose levels of streptozotocin-induced 
diabetic Balb/c mice after intraportal transplantation of (a) 500 control islets (n = 9), (b) 
1000 control islets (n = 4), (c) 500 PEG-islets (n = 6), or (d) 1000 PEG-islets (n = 5). 
Graft failure was defined as two consecutive plasma glucose determinations ≥ 200 
mg/dL. 
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Figure 4. Histochemical analysis of (a) control islets and (b) PEG-islets transplanted 
into the liver of diabetic mice through the portal vein by hematoxylin-eosin staining, 
and (c) PEG-islets by insulin staining. These grafts were retrieved at 1 hr and 1 day 
post-intraportal transplantation. The graft obtained 1 hr after transplantation was also 
stained for insulin and the nucleus (Hoechst 33342). 
 
Figure 5. Changes in the blood insulin levels of diabetic mice after intraportal 
transplantation of control islets (closed circles, n = 7) or PEG-islets (open circles, n = 7). 
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Post transplantation into liver (min)
Figure 5
Number Graft survival days Mean + SD
control islets 500 0, 0, 0, 1, 2, 3, 3, 3, 4 1.8+1.6
1000 6, 7, 8, 9 7.5+1.7
PEG-islets 500 4, 4, 5, 5, 6, 6 5.0+0.9
1000 6, 6, 6, 7, 7 6.3+0.3
Table 1. Graft survival days after transplantation.
Graft failure was defined as two consecutive plasma glucose 
determinations ≥ 200 mg/dL. 
p < 0.01
